Takeda's $4 Billion Bet on a Pill Just Paid Off in a Big Way
Takeda's psoriasis pill zasocitinib just more than doubled Sotyktu's skin clearance rate in a direct head-to-head trial, validating a $4 billion acquisition bet. The result could reshape the entire oral psoriasis market before the drug even hits pharmacy shelves.
Imagine buying a house for $4 billion, sight unseen, based on blueprints alone. That's essentially what Takeda did in early 2023 when it acquired Nimbus Therapeutics' TYK2 program. This week, the inspection report came back, and the house is gorgeous.
Takeda's experimental psoriasis pill, zasocitinib, just demolished Bristol Myers Squibb's Sotyktu in a direct head-to-head Phase 3 trial. More than 35% of patients on zasocitinib achieved complete skin clearance at 16 weeks, a rate 2.5 times higher than what Sotyktu delivered in the same study. That's not a marginal win. That's running a different race entirely.
The Trial That Changes Everything
The study, called LATITUDE Atlas, did something unusual in pharma: it put the new kid directly against the reigning champ. Most drug trials compare against placebo (basically sugar pills), which makes almost anything look impressive. Head-to-head trials are riskier, bolder, and far more informative. Takeda chose violence, and it worked.
Zasocitinib hit statistical superiority on every measure that mattered. The primary endpoint was PASI 100, which is the gold standard in psoriasis: literally zero visible disease. The drug also beat Sotyktu on PASI 90 (nearly clear skin) and sPGA 0 (another "clear skin" rating used by dermatologists). Patients on zasocitinib started pulling ahead as early as week 8, meaning the drug kicked in faster, too.
For context, Sotyktu's own pivotal trials showed PASI 100 rates of roughly 10 to 14%. Getting above 35% in a head-to-head setting is the kind of number that makes dermatologists sit up straight.
Why These Two Drugs Aren't Created Equal
Both zasocitinib and Sotyktu belong to the same drug class: TYK2 inhibitors. Think of TYK2 as a molecular switch inside immune cells that, when stuck in the "on" position, drives the overactive inflammation behind psoriasis. Both drugs flip that switch off by binding to the same spot on the protein (the JH2 pseudokinase domain, if you're keeping score).
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
But zasocitinib does it with dramatically more precision. In lab tests, it shows over one-million-fold selectivity for TYK2 over related enzymes called JAK1, JAK2, and JAK3. Sotyktu's selectivity for TYK2 over JAK1? About >100-fold. That's the difference between a sniper rifle and a shotgun.
This matters because hitting JAK1, JAK2, or JAK3 by accident is what gave older JAK inhibitors their infamous safety baggage: boxed warnings about blood clots, heart problems, and cancer. By staying locked onto TYK2 alone, zasocitinib sidesteps those concerns, at least in theory.
The pharmacology tells a similar story. At its clinical dose, zasocitinib keeps TYK2 suppressed for roughly 24 hours a day, achieving about 90% daily inhibition of the target. Sotyktu, at its approved dose, maintains meaningful TYK2 suppression for only about 9 hours, translating to roughly 50% daily inhibition. It's the difference between keeping your foot on the brake all day versus tapping it a few times.
The $4 Billion Vindication
When Takeda announced the Nimbus acquisition in December 2022, plenty of observers raised eyebrows. Four billion dollars upfront (with another $2 billion in potential milestones) for a drug that was still in mid-stage trials? The price tag felt aggressive.
Three years later, it looks increasingly prescient. Zasocitinib has now cleared two Phase 3 trials in psoriasis, with a third ongoing. In the earlier placebo-controlled studies, about 52 to 61% of patients hit PASI 90 and roughly 25 to 33% reached PASI 100 at 16 weeks, crushing both placebo and apremilast (Amgen's Otezla). Analysts at Jefferies have called the overall package "best-in-class Phase 3 results."
Takeda plans to file for FDA approval starting this fiscal year, which began in April 2026. If the agency follows its standard review timeline, a decision could land sometime in calendar 2027.
Bad News for Bristol Myers
For BMS, this is an uncomfortable development. Sotyktu was supposed to be a blockbuster. Pre-launch forecasts had it clearing $1 billion by 2024 and approaching $2.4 billion by 2026. The reality? About $291 million in global sales for 2025, growing at a respectable 19% clip but from a painfully small base.
The drug has faced a cocktail of challenges: stubborn payer resistance, cautious physician adoption, and stiff competition from Amgen's entrenched Otezla franchise. BMS recently pushed back its overall new-product revenue milestone by a full year, partly because of Sotyktu's sluggish uptake.
Now add a rival that more than doubles your best efficacy number in a direct comparison. That's not a headwind; it's a wall.
BMS does have a card to play. Sotyktu just won FDA approval for psoriatic arthritis in March 2026, making it the first TYK2 inhibitor with that label. About a third of U.S. rheumatologists had started patients on it within two months of the PsA launch. But zasocitinib is chasing the same expansion, and Takeda has signaled plans for PsA, inflammatory bowel disease, and lupus.
The Bigger Picture: A Pill That Works Like a Biologic
The psoriasis market is in the middle of a generational shift. For years, the most effective treatments required injections: drugs like Skyrizi, Tremfya, and Cosentyx. Patients tolerated the needles because nothing else came close.
Now, a new wave of oral therapies is closing that gap. Zasocitinib's PASI 90 rates in the low-to-mid 50s start brushing up against what some injectable biologics deliver. Johnson & Johnson's newly approved oral IL-23 blocker, icotrokinra, adds another potent pill to the mix. And Alumis has its own TYK2 inhibitor, envudeucitinib, which has completed Phase 3 and is headed toward an NDA filing.
Analysts project oral psoriasis therapies will grow at roughly 11% or more annually over the next several years, outpacing the broader market. The pitch is simple: biologic-level results without the needle, the infusion center, or the cold chain shipping.
What's Left to Prove
Zasocitinib isn't approved yet, and skeptics have legitimate questions. Long-term safety data beyond 16 weeks remains thin. The FDA could impose class-level warnings that blunt the drug's commercial edge. And entering a market where Sotyktu, icotrokinra, and Otezla are already fighting for shelf space means Takeda will need flawless commercial execution.
But the clinical story is hard to argue with. When your drug more than doubles the competition's best number in a fair fight, the conversation shifts from "if" to "when." Takeda bet $4 billion that this molecule was special. Right now, it's looking like they got a bargain.
Clinical & Regulatory
5 min read
The FDA Just Declared War on Cheap Ozempic
The FDA just launched its largest-ever coordinated crackdown on compounding pharmacies selling cheap versions of Ozempic and Wegovy, explicitly targeting Hims & Hers in the process. A multibillion-dollar grey market is being dismantled, and the fallout is reshaping telehealth, Big Pharma, and patient access to the most popular drugs in America.
